kong – 第 24 页

兴业银行资本项目数字化服务试点落地

23 6 月, 2022

HONG KONG, Jun 23, 2022 - (亚太商讯 via SEAPRWire.com) - “资本项目业务可以通过线上申请，我们足不出户就能完成资本项目登记，尤其是疫情防控期间，还减少了线下接触风险，‘兴业单证通’简直太方便了！”福州A企业财务负责人高兴地说。据悉，B企业是一家外商投资企业，主要从事房屋建筑及项目工程承包业务，为进一步拓宽国内市场，计划使用其股东境外汇入的资本金开展境内投资。根据资本项下便利化政策，非投资性外商投资企业资本金可用于境内股权投资，便利了企业境内投资。被投资企业A在完成相关备案手续后，急需通过银行完成接收境内再投资登记手续，以便进行后续资金的划转使用。兴业银行福州分行在了解到A企业满足资本项下便利化政策后，积极辅导企业通过该行“兴业单证通”线上办理资本项目登记手续，实现在线填写申请表、扫描上传审核材料，一键提交银行办理，足不出户完成资本项目接收境内再投资登记手续，极大提高了效率，用时不到30分钟。资本项目业务实现线上高效快捷办理，得益于兴业银行在外汇局福建省分局的大力支持下，成功获批国家外汇管理局资本项目数字化服务试点资格。此项试点业务允许银行在符合现有资本项目业务审核原则和档案管理要求的前提下，支持企业通过“兴业单证通”线上办理资本项目线上登记、账户入账、资本项目收入支付便利化、资本项目外汇收入意愿结汇和非便利化资本项目资金境内支付等高频业务，真正实现资本项目外汇服务的“触手可及”。今年以来，兴业银行积极响应中国人民银行、国家外汇管理局关于做好疫情防控和经济社会发展金融服务的23条举措，不断优化跨境业务办理流程和服务，进一步提升跨境业务数字化水平，支持外贸稳增长。数据显示，1-5月，兴业银行实现本外币跨境结算量1253亿美元，同比增长19%。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

ACN Newswire

医思健康公布2021/22年度全年业绩

23 6 月, 2022

HONG KONG, Jun 23, 2022 - (亚太商讯 via SEAPRWire.com) - 香港最大非医院医疗服务机构* ── 医思健康（「公司」，连同附属公司，总称「集团」；香港联交所股份编号：2138）公布截至2022年3月31日止财政年度（「年内」）之经审核全年业绩。业绩摘要-- 集团销售额录得创新高31.22亿港元，同比上升40.7%-- 集团总收入大幅上升40.3%至29.20亿港元，创历史新高-- 医疗分部收入同比大幅上升64.6%至创新高16.89亿港元，占比进一步提升至57.9%-- 息税折旧及摊销前之盈利（「EBITDA」）大幅增长35.0%至创新高 5.36亿港元-- 集团税后净溢利为 2.71亿港元，每股基本盈利为17.1港仙-- 拟派末期股息每股4.2港仙（连同中期股息10.2港仙，全年共派发股息14.4港仙），全年派息比率为84.2%-- 截至2022年3月31日，集团已完成6.41亿港元估值的收并购，业务横跨兽医，牙医及多个医学专科，深化医疗服务布局-- 医疗服务覆盖医疗专科数目增加至29个，全职注册专属医生团队人数增长至251人-- 集团的服务点数量扩张至147个，总楼面面积同比增加约34.2%至534,000平方呎-- 集团于疫情期间积极承担社会责任，调配资源提供多种抗疫服务，同心抗疫-- 根据弗若斯特沙利文的数据显示，以2021年收入计算，集团维持香港最大的医疗服务提供商（非医院）的领先地位回顾年内，香港爆发第五波新冠疫情，集团业务在充满挑战的经营环境下依然持续增长，进一步巩固其行业领先地位。集团录得创新高 31.22亿港元销售额，同比增加40.7%。同时，集团录得 29.20亿港元收入，同比上升40.3%，创历史新高。得益于集团在科技，服务，品牌及公司文化的长期投入，以及集团灵活且高效的管理运营，集团内生业务的收入较上年度上升49.8%至27.61亿港元，占比进一步提升至94.6%。年内，医疗服务业务板块仍然为集团最主要的收入驱动力，医疗服务业务录得新高16.89亿港元收入，同比大幅上升64.6%。集团息税折旧及摊销前之盈利为5.36亿港元，按年增长35.0%。集团税后净溢利为2.71亿港元，较上年度上升19.9%。然而，由于集团在香港第五波疫情期间配合政府防疫要求，美容养生业务曾暂停营业共104日，期内暂停营业84日，致使净溢利承压。本公司权益股东应占净溢利上升2.4%至 1.98亿港元。每股基本盈利为17.1港仙，去年同期为18.8港仙。董事会建议派发末期股息每股4.2港仙。年内集团客户服务个人客户数稳步增加至182,300人(1)，老客户贡献之收入占集团本财年收入的64.3%(2)。客户忠诚度维持在高水平，客户的复购率达90.2% (3)。集团构建的大健康闭环生态系统发挥协同效益，年内有超过27.5%的客户跨品牌进行消费(4)。同时，集团一直保持着优质的服务质量，客户满意度高达99.96%(5)。根据弗若斯特沙利文的数据显示，以2021年收入计算，集团保持了香港最大的医疗服务提供商（非医院）的领先地位。集团通过内生增长与并购进一步扩张服务点数量。集团本财年内成功进入兽医领域，收购了7间宠物医院，2间宠物用高端影像中心。截至2022年3月31日，集团于香港营运共127个服务点，澳门4个及中国大陆16个，总楼面面积共约534,000平方呎。本财年净增加的136,000平方呎楼面面积中71.9%来自医疗业务，28.1%来自医美业务及美容养生服务业务。医疗服务业务快速增长医疗业务方面，年内市场对集团提供的医疗服务维持旺盛需求，集团通过内生增长与并购持续扩大市场份额。年内集团医疗分部收入同比大幅上升64.6%至创新高16.89亿港元，占集团总收入比例进一步提升至57.9%，其中内生增长及并购增长的贡献分别为95.0% 及5.0% 。内生增长受益于抗疫相关服务需求急增及市民健康管理意识持续提升。于本财年，集团于医疗板块共执行4.61亿港元估值的收并购，覆盖牙医及多个医学专科。集团医疗服务能力进一步提升，覆盖医疗专科数目达29个，全职注册专属医生团队人数进一步增长至251人。美学医疗及美容养生服务业务维持韧性美学医疗及美容养生业务方面，得益于集团多年来累积的坚实的品牌力，集团得以在波动的环境下维持业务的稳定发展。年内，集团美学医疗及美容养生分部贡献收入10.91亿港元，同比上升10.2%，其中来自中国香港部分维持稳定，达8.05亿元港元，来自中国大陆收入同比上升28.4%至1.73亿港元；受益于医疗旅游的强劲复苏，来自中国澳门收入大幅上升119.6%至1.13亿港元。支持小区同心抗疫承担社会责任集团作为香港领先的民营健康医疗服务机构，在疫情期间积极承担社会责任，提供多种抗疫服务，例如集团旗下诊所推出遥距医疗及送药服务，亦透过旗下化验所提供政府认可的新冠病毒核酸检测及抗体检测服务。集团亦为市民提供新冠疫苗注射服务，并联合慈善团体捐赠快速检测包予有需要人士。订立2030年可持续发展目标集团将可持续发展目标融入业务实践，积极采取措施成立可持续发展工作小组，并在董事会监督下制定长期可持续发展战略。年内集团携手第三方机构完成了利益持份者参与调研，并以调研结果为依据订立了2030年可持续发展目标。我们发现运营及信息科技系统相关之风险是集团利益持份者较关注的议题，集团携手第三方机构检视了目前的数据管治框架并给出了优化意见。报告期后的业务最新发展集团于报告期后，宣布了两项医疗资产收购、一个合资项目及签订首笔可持续发展表现挂钩贷款，进一步提升集团的医疗板块市场份额，深化医疗服务布局。2022年4月7日，集团宣布以总现金代价1,575万港元收购大埔一家兽医医院的75%已发行股本，待收购完成后，集团将于香港经营8家兽医医院、2间动物影像中心；2022年 5月 23日，集团宣布以总现金代价4,125万港元收购美邦医学体检中心及其附属公司75%已发行股本，于收购完成后，集团将运营总计6间体检中心，全面覆盖香港新界，九龙及港岛，实现对香港体检市场的进一步整合；2022年6月6日，集团宣布开创医疗业务租户与业主双边赋能合作，与房地产投资管理公司凯龙瑞集团及亚洲联合基建控股有限公司成立合资公司，联合于香港兴建优质的医疗级别专用大厦。大厦落成后集团将成为主要承租人。集团已有条件同意向合资公司作出不多于2.75亿港元的初步出资，占合资公司发行股本总额的30%。2022年6月21日，集团订立首笔总额7亿港元的可持续发展表现挂钩贷款，成为香港医疗健康服务行业中首家订立此类贷款的公司，彰显集团在行业中的领先地位，并再次肯定可持续发展在集团未来发展战略中的重要性。医思健康主席、执行董事兼行政总裁邓志辉先生总结：「集团相信医疗市场在充满挑战的经营环境下将总体维持韧性，且长期而言公营及民营医疗健康领域的合作将推动香港民营医疗市场的支出不断增加。展望未来，集团将持续拓展医疗服务以及美学医疗及美容养生两大板块的业务多元化水平，进一步满足客户的需求，扩展服务范围。集团亦将持续推进与科技，电讯，房地产，保险及制药领域巨头的深度合作以不断完善医思闭环大健康生态系统。集团将遵守可持续发展之相关承诺。展望未来，集团期待携手价值观相同的持份者，在可持续发展的道路上不懈努力。集团将不断完善可持续发展战略，实现公司乃至小区之长远福祉。」关于医思健康香港最大非医院医疗服务供货商*医思健康以预防及精准医疗为业务核心，透过多元服务整合发展医疗人工智能，配套高端品牌及优质客户服务，致力为客户提供最专业、安全、有效的医疗健康服务。集团为恒生综合指数成份股及MSCI香港小型股指数。集团目前直营的诊所／服务中心主要位于大湾区，提供一站式医疗及健康服务。服务涵盖面极广，旗下主要知名服务品牌包括连续多年荣膺全港第一的一站式医学美容解决方案DR REBORN、专业健发中心发森及多元化多维度的医学服务包括：健康管理中心香港仁和体检中心、疫苗中心香港安苗医疗中心、普通科门诊未来医生、全港最大一站式痛症管理平台纽约脊骨物理治疗中心、全方位牙科服务中心庇利积臣牙科医务所，EC DENTAL CARE及恒健牙科医务所、高端影像中心博思医学诊断中心、仁生肿瘤及癌症中心、内视镜及日间医疗中心仁辉专科中心、专科中心进汇医务中心，联汇专科，新医疗中心、儿科专科汇儿儿科医务中心、妇产科专科卓越医务中心及产前诊断中心、栢立医学化验所、眼科中心唯视眼科和医思兽医医院及影像中心。*根据弗若斯特沙利文公司按2020年及2021年收入计算进行的独立研究1. 以年内收入计2. 老客户年内收入贡献除以该财年总收入3. 21财年客户于22财年收入贡献除以21财年总收入4. 年内消费多于一个品牌服务客户数除以年内全年客户数5. 100%减重大负面回馈占本集团该年内总收入比例若有进一步垂询，请联络：iPR奥美公关刘丽恩 / 陆咏诗 / 叶子欣电话：(852) 2136 6952 / 2169 0467 / 3920 7649传真：(852) 3170 6606电邮：ech@iprogilvy.com Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

ACN Newswire

EC Healthcare Announces FY2021/22 Annual Results

23 6 月, 2022

HONG KONG, Jun 23, 2022 - (ACN Newswire via SEAPRWire.com) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong, announces today its audited annual results for the fiscal year ended 31 March 2022 (the "Year").Business Highlight -- Sales volume achieved record high of HK$3,122.3 million, up 40.7% YoY-- Total revenue surged 40.3% YoY to a record high of HK$2,919.5 million-- Revenue from medical services segment increased significantly by 64.6% YoY to a record high of HK$1,689.0 million, boosting its revenue contribution to 57.9%-- Earnings before interest, taxes, depreciation, and amortization ("EBITDA") increased by 35.0% YoY to a record high of HK$536.4 million-- Net profit after tax for the Year was HK$270.5 million, increased by 19.9% YoY, basic earnings per share was 17.1 HK cents-- The board of directors (the "Board") proposed final cash dividend of 4.2 HK cents per share, which together with the interim dividend of 10.2 HK cents per share, will bring the total annual dividend to 14.4 HK cents per share, representing an annual dividend payout ratio of 84.2%-- As at 31 March 2022, the total valuation of the Group's M&A transactions completed was HK$641.1 million, spanning across veterinary, dental, and various medical specialties, which further strengthened the Group's medical services layout -- The Group's suite of medical services extends to 29 specialist disciplines, and the number of full-time and exclusive registered practitioners has increased to 251-- Total number of service points increased to 147, total gross floor area increased by 34.2% YoY to approximately 534,000 sq. ft-- The Group has been committed to its social responsibility during the COVID-19 pandemic by deploying resources to provide a wide range of anti-pandemic services, aiding the joint fight against the virus-- The Group maintained the leading role as the largest medical service provider (non-hospital) in Hong Kong in terms of revenue in 2021, according to Frost and SullivanDuring the Year, the Group's businesses demonstrated strong resilience to grow continually amidst a challenging operating environment caused by the fifth wave of the COVID-19 outbreak in Hong Kong, and further consolidated its leading position in the industry. The Group posted a record high sales volume of HK$3,122.3 million, up 40.7% year-on-year ("YoY"), while revenue also surged by 40.3% YoY to a record high of HK$2,919.5 million. Organic revenue increased by 49.8% YoY to HK$2,761.4 million, accounting for 94.6% of the total, thanks to the Group's long-term investments in technology, service, branding, corporate culture, and its flexible and effective operations management. During the Year, medical segment continued to be the key growth driver as medical revenue marked record high and increased significantly by 64.6% YoY to HK$1,689.0 million. The Group's EBITDA (earnings before interest, taxes, depreciation, and amortization) increased by 35.0% YoY to a record high HK$536.4 million. The Group's net profit after tax for the Year increased 19.9% YoY to HK$270.5 million, however net profit margin is under pressure of the suspension of the Group's beauty and wellness businesses in Hong Kong for a total of 104 days (total 84 days during the Year) in compliance with government pandemic control measures.The net profit attributable to equity shareholders of the Company increased by 2.4% YoY to HK$197.5 million. Basic earnings per share was 17.1 HK cents, compared to 18.8 HK cents for the same period last year. The board of directors proposed a final cash dividend of 4.2 HK cents per share. During the Year, the number of unique customers steadily increased to 182,300 (1) during the Year and the contribution from existing customers accounted for 64.3% (2 )to the Group's total revenue. Customer loyalty remained high with repurchase purchase rate of 90.2% (3). Driven by the synergies created by the Group's enclosed healthcare ecosystem, over 27.5% (4) of its customers have made purchases across its various brands in the Year. Meanwhile, the Group has maintained premium service quality with 99.96% (5) of customers' satisfaction rate. The Group maintained its leading role as the largest medical service provider (non-hospital) in Hong Kong in terms of revenue in 2021, according to Frost and Sullivan.Our number of service points increased through organic expansion and acquisition growth. During the Year, we have ventured into veterinary business and acquired 7 vet clinics and 2 vet advanced imaging centers. As at 31 March, 2022, the Group had total number of service points of 127 in Hong Kong, 4 in Macau and 16 in Mainland China with total gross floor area of approximately 534,000 sq. ft. Out of the net increase of approximately 136,000 sq. ft. floor area in FY2022, 71.9% came from the medical business and 28.1% from the aesthetic medical and beauty and wellness services business.Strong growth in medical segmentFor medical business, demand for the Group's medical services remained strong in FY2022. The Group continued to grow its market share through both organic and M&A growth strategies. Revenue from the Group's medical services segment increased significantly by 64.6% YoY to a record high HK$1,689.0 million, boosting its revenue contribution to 57.9%, of which organic expansion and M&A completed during FY22 accounted for 95.0% and 5.0% respectively. Organic growth is driven by surged demand for COVID-19 related services and rising healthcare sentiment. During FY22, the total valuation of acquisitions completed in medical segment was HK$460.7 million, spanning dental and various medical specialties. The Group's suite of medical services spans 29 specialist disciplines, and our headcount of full-time and exclusive registered practitioners has increased to 251.Resilient result from aesthetic medical and beauty and wellness services segmentFor aesthetic medical and beauty and wellness business, the Group demonstrated its resilience by achieving steady growth, thanks to the brand capital established over the years. During the Year, revenue contributed by aesthetic medical and beauty and wellness services increased by 10.2% YoY to HK$1,091.2 million. Revenue from Hong Kong remains stable at HK$804.7 million. Revenue from Mainland China increased by 28.4% YoY to HK$173.2 million, while revenue from Macau, China surged 119.6% YoY to HK$113.4 million due to a strong recovery of medical tourism.Embracing social responsibility by stepping up our response in the community during COVID-19As Hong Kong's leading private healthcare service provider, the Group stepped up during the COVID-19 pandemic to provide a wide range of anti-pandemic measures to the public. For example, we offered telemedicine and drug delivery services through our clinics as well as government-approved nucleic acid tests (RT-PCR) and antibody tests through our accredited laboratories. The Group also provides COVID-19 vaccinations to the public and has joined hands with charitable organizations to donate rapid test kits to those in need.Set up 2030 sustainability goals To assimilate sustainability into our business, the Group has taken a proactive approach to set up a sustainability working group with board of directors' oversight to execute our sustainability strategy. We have conducted stakeholder engagement surveys and set up our 2030 sustainability goals based on the findings. Operation & IT-related risks atop our stakeholders' concerns, we will further advance our operation protocols and have engaged third party consultant to review our data governance policy. Latest Business Developments after the Reporting PeriodAfter the annual reporting period, the Group has announced the acquisitions of two new medical businesses and formed one joint ventures, which will further expand the market share of the Group's medical business and extend the scope of the Group's medical services and its business presence.On 7 April 2022, the Group announced to acquire 75% of the issued share capital of a veterinary hospital in Tai Po for a total consideration of HK$15.75 million in cash. Upon completion, the Group will operate a total of 8 veterinary hospital, 2 veterinary imaging centers in Hong Kong.On 23 May 2022, the Group announced to acquire 75% of the issued share capital of Mobile Medical International Holdings Limited and its subsidiaries for a total consideration of HK$41.25 million in cash. Upon completion, the Group will operate a total of 6 health screening services centers, covering New Territories, Kowloon and Hong Kong Island, thereby further consolidating the health screening market in Hong Kong.On 6 June 2022, the Group announced to spearhead an unprecedented medical tenant - landlord collaboration and formed a joint venture with a real estate investment management company, KaiLong Group and Asia Allied Infrastructure Holdings Limited to co-build a premium purpose-built medical grade building in Hong Kong. The Group will be the anchor tenant of this Medical Building upon completion. The Group has conditionally agreed to make initial capital contributions to the joint venture company of up to HK$275 million, which will represent 30% of the total enlarged issued share capital of the joint venture company.On 21 June 2022, the Group signed its first sustainability-linked facility ("SLL Facility") totaling HK$ 700 million. This inaugural dual-tranche SLL Facility is a first-of-its-kind for a healthcare services provider in Hong Kong, complementing the Group's established status as a leading industry pioneer and reaffirms the importance of sustainability in the Group's future growth strategy. Mr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of EC Healthcare said, "The Group believes the medical market will remain relatively resilient under the challenging environment and public-private partnership will continue to increase Hong Kong's private medical spending in the long run. Looking forward, the Group we will diversify within medical and beauty sectors, which allow us to further increase in service offerings to our customers to better meet their needs. We will also continue to expand our strategic partnerships with key players in technology, telecom, property, insurance and pharmaceutical industries to form our healthcare ecosystem. The Group committed to uphold sustainability principles. Moving forward, we will excel through our sustainability journey together with our much-valued stakeholders. We will also be proactive in continuously refining our strategies for the overall welfare of our company and the greater community."About EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of the Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, a professional hair care center HAIR FOREST, primary care clinics jointly established with health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, General outpatient clinic Tencent Doctorwork, the largest one-stop pain management centre in Hong Kong New York Medical Group, the comprehensive dental centres Bayley & Jackson Dental Surgeons, EC DENTAL CARE and Health and Care Dental Clinic, a advanced diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic PREMIER MEDICAL CENTRE, SPECIALISTS CENTRAL and NEW MEDICAL CENTER, a paediatric centre PRIME CARE, a gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, PathLab Medical Laboratories, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 20211. Based on revenue for the year2. Revenue contribution by existing customers to the total revenue for the year3. Customers of FY21 contribution in FY22 divided by the total revenue in FY214. Number of customers who purchased services from more than one brand for the year divided by total number of customers for the year 5. 100% minus the percentage of material unfavourable feedback of total revenue for the yearFor further information, please contact: iPR Ogilvy Limited Callis Lau / Lorraine Luk / Charmaine Ip Tel: (852) 2136 6952 / 2169 0467 / 3920 7649 Fax: (852) 3170 6606 Email: ech@iprogilvy.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

思摩尔国际荣获《机构投资者》最受尊崇公司等五项大奖

23 6 月, 2022

HONG KONG, Jun 23, 2022 - (亚太商讯 via SEAPRWire.com) - 全球最大电子雾化设备制造商 - 思摩尔国际控股有限公司(「思摩尔」或「公司」，连同其附属公司，统称「集团」，股份代号：6969.HK)宣布，在全球最具影响力的金融杂志之一《机构投资者》杂志公布的“2022年亚洲（日本除外）管理团队”榜单中，思摩尔在138间获得提名的亚洲日用消费品企业中脱颖而出，被评选为日用消费品企业第三名，并获得重量级奖项“最受尊崇公司”。同时，公司荣获“最佳社会及企业管治（ESG）”第二名、“最佳首席财务官”第三名、“最佳投资者关系方案” 第二名及“最佳投资者关系专业人员”第二名等多个单项大奖。《机构投资者》杂志由Gilbert E.Kaplan先生在1967年在纽约创立，为全球领先的企业管治及投资者关系研究公司，其母公司欧洲货币机构投资者集团，是伦敦证券交易市场的上市公司，同时是富时250指数的成员之一。《机构投资者》的奖项评选活动开展已超过50年。作为全球范围内最为顶尖及受业界关注的金融刊物，该杂志每年都会邀请全球顶尖金融机构的买方分析师、基金经理和卖方研究人员作为评委，评选出在企业管治及投资者关系管理方面表现卓越的上市公司。该奖项每年评选标准非常严格，每次评选皆会引起资本市场讨论热潮，赢得业界的高度尊重和认可，对市场具有风向标作用。在2022年的排名中，共有5,524名买方分析师及卖方分析师从财务讯息披露、企业管治及投资者关系等核心维度，从18个行业共1,612家获得提名的上市公司中进行评选，并最终评选出46家最受尊崇公司。自2020年上市以来，思摩尔一直重视投资者关系管理及维护工作。公司致力通过专业、及时、全面的市场交流及信息披露，实现与资本市场的高效顺畅沟通。疫情期间，公司通过业绩发布会、券商策略会、反向路演、定期投资者调研及产品发布会等多渠道与资本市场保持双向沟通，得到了资本市场的一致认可。此外，思摩尔持续深化ESG战略并将可持续发展作为公司日常运营和业务决策的重要一环。2021年1月，公司获得全球最大指数公司MSCI（明晟）ESG的A级评价并在最新一期的评级中维持A级评价。此次《机构投资者》ESG奖项的颁发，是对公司在可持续性发展、社会责任及企业管治方面的重要认可。在2021年，思摩尔实现温室气体排放密度同比下降约16%，用水消耗密度同比减少约9.4%的优异成果。同时，年内公司定下四大行动方向及目标：2050年前实现运营排放碳中和、2030年前实现30%能耗来自可再生能源、妥善处置废弃物、鼓励回收、充分利用水资源及减少水消耗，致力在企业运营的全方位实现“零碳企业”这一目标。此外，在过去数年，公司亦不遗余力地参与不同类型的社区贡献活动，贡献范畴包括青年学习及发展、抗洪救灾、社区参与、扶贫济困和抗疫等，其中在2021年集团公益活动投入资金超过1,130万元人民币，员工义务工作时数超过500小时，总培训时数超过346万小时。思摩尔董事会主席兼行政总裁陈志平表示：“本次公司在《机构投资者》荣获诸多重要奖项，是国际资本市场对思摩尔过去业务表现、企业管治、ESG领域、投资者关系维护等工作的高度认可。未来，思摩尔将再接再厉，积极主动做好投资者关系管理工作，争取再创佳绩。同时将继续坚持长期主义和技术制造领先的战略，专注打造全球领先的雾化科技平台，为客户、合作伙伴、员工、股东乃至全社会创造长期价值。” 关于思摩尔国际控股有限公司思摩尔业务始于2006年，是全球领先的雾化科技解决方案提供商。自成立以来，思摩尔始终坚守“雾化让生活更美好”的使命，持续探索雾化技术创新与应用边界，突破想象，超越期待。凭借强大的研发实力和领先的制造能力，思摩尔已成为全球最大的电子雾化设备制造商，在全球拥有10所基础技术研究院，产品远销50多个国家和地区。2020年7月10日，思摩尔正式在香港联合交易所上市（股份代号：6969.HK）。2021年，思摩尔以22.8%的雾化器市场份额，位列全球第一。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

服务新市民有新招兴业银行被点赞

23 6 月, 2022

HONG KONG, Jun 23, 2022 - (亚太商讯 via SEAPRWire.com) - 近日，中国银保监会办公厅发布了《关于银行业保险业加强新市民金融服务有关情况的通报》，多家银行保险机构因地制宜积极探索加强新市民金融服务，助力稳定宏观经济大盘，取得良好成效。其中兴业银行因优化住房金融服务、提升开户服务效能等基础金融服务，支持新市民职业技能培训等方面的创新举措，被点名表扬。租购并举打出安居服务“组合拳”“住有所居”是老百姓心中最朴素的愿望，也是新市民最为关心的问题之一。兴业银行通过优化房贷授信政策，进一步开放对符合条件的异地户籍客户个人住房贷款业务办理通道，让更多新市民可以享受到与当地居民同等的房贷政策，在新城市安家落户。考虑疫情期间不少新市民面对生活与就业双重压力，兴业银行专门开发了“随薪供”房贷还款方式，给予房贷客户最长3年期限的，只还利息，暂缓归还本金服务，客户可通过手机银行在线申请办理，操作简单，即时生效，让客户尽享便利。大力发展住房租赁市场是今年政府工作报告提到的一项重点工作。兴业银行子公司兴业消金锚定新市民进入职场初期的租房需求，推出“立业计划”，为应届毕业生等提供前6个月免还本安居租房贷款，力争实现新市民的‘职住平衡’。同时兴业银行还上线了对接政府住建系统的租赁资金监管平台，有力保障租客的资金安全，解决新市民租房的后顾之忧。据介绍，从去年10月起，兴业银行在全国范围打造“兴e家”智慧社区服务平台，为新市民提供包括物业管理、租房信息、金融服务、房屋租赁等一揽子服务，构建住房租赁生态圈。”量身定制让新市民融入新生活我国目前有近3亿农民工，是推进我国新型工业化、城镇化建设的重要力量。兴业银行针对这一庞大的新市民群体，在股份制银行中首家推出以“关爱农民工”为主题的普惠金融综合服务方案，并为其量身定制专属银行卡——“民薪卡”，提供免收工本费、年费、小额账户管理费、短信服务等优惠，以及专属增值权益、专属金融产品等服务，有效保障农民工这一新市民群体的合法权益，目前民薪卡在全国范围内发行量已逾20万张。为促销费稳增长，更好满足新市民衣食住行消费需求，兴业银行紧跟市场步伐，推出线上消费贷款产品—-“兴闪贷”，通过引入公积金、社保等缴交信息补充征信，可发放最高不超过20万元的信用免担保消费贷款。“办理兴闪贷整个过程不过几分钟，其中自动化审批环节仅需1分钟就能够出结果，贷款审核通过后我们会用短信告知客户贷款额度和提款有效期，对客户而言非常便利。”兴业银行零售信贷部负责人表示。子女教育，是很多新市民急难愁盼的问题。兴业银行子公司兴业消金推出“兴才计划”，为新市民子女在接受高等教育期间的学费、生活费、教育培训等方面的开支提供贷款支持，最长贷款期限20年，并实行优惠贷款利率和在校期间只需还利息的灵活还款方式，推行贷后“90天无条件退贷”政策，减轻客户还款压力，目前已累计为3.9万名客户提供贷款14.3亿元。此外，兴业消金还在22所高校挂牌成立励志成长基地，帮扶家庭经济困难的学生开展勤工助学、技能培训和就业竞争力提升的公益性服务，帮助更多新市民子女完成大学深造、踏上工作岗位。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

ACN Newswire

Nomination Opens for “Directors Of The Year Awards 2022”

22 6 月, 2022

HONG KONG, Jun 22, 2022 - (ACN Newswire via SEAPRWire.com) - The "Directors Of The Year Awards 2022" organised by The Hong Kong Institute of Directors ("HKIoD") is open for nomination now. Themed "From Resilience to Sustainability", the Awards this year recognises directors and boards capable of leading their companies in adapting to changes and, with outstanding governance thinking and practical strategies skills, taking their companies towards sustainable development in the ever-changing business environment.Dr Christopher To, Chairman of HKIoD, said, "Leadership in crisis calls for the ability to rethink and redefine some long-standing values or structure, and also the courage and strength to brave the uphill. In the at large uncertain environment now, we must keep learning, evolving, adapting and changing, to make sure the 'new normal' is a 'better normal'. Marking HKIoD's 25th Anniversary, this year's award is themed 'From Resilience to Sustainability', reflective of what we have learnt over the years. Resilience is the most important quality a company needs to survive in the ever-changing world and sustainability is the ultimate goal of every company. I hope all of you can nominate directors and boards standing out in these two aspects, that we may take as examples to inspire all in the business sector to excel."Mr Richard Ho, Chairman of 2022 Directors Awards Organising Committee, said, "When discussing the award theme this year, the Committee thought though the global scene is still unpredictable and challenging, it has become clearer. Thus, we decided to have 'From Resilience to Sustainability' as the theme easier to grasp. We hope to commend those outstanding leaders who braved the challenges from the pandemic and helped their companies achieve good results, and also to remind those in different sectors to set their eyes on long-term strategy and advance towards their sustainable development goal."Dr Carlye Tsui, CEO of HKIoD, said, "All of us, companies or individuals, have gotten used to staying clam in the turbulent environment. With our feet firmly on the ground, it is time that we head again towards our long-term targets. Directors, as leaders of a company, should be sensitive at all times to changes in the market and plan the 'next step' to take. For example, Web3.0 is the latest and a major trend likely to bring revolutionary changes in the near future to all of us. Business leaders who do not have a good understanding of it might just miss the opportunities that come with it. Offering diverse and innovative courses, HKIoD helps members refresh what has been learnt and acquire new knowledge, so that they may be ready any time to take their companies forward."Nomination for the Awards will close on 1 August 2022. On the Judging Panel are business leaders, professionals and regulatory body representatives in Hong Kong. The Directors Of The Year Awards 2022 recognise excellence in the following categories:Company Categories / Director Categories1. Listed Companies / 1. Executive Directors2. Non-Listed Companies / 2. Non-Executive Directors3. Statutory/Non-Profit-Distributing Organisations* / 3. BoardsNotes: *A non-profit-distributing organisation is defined as an organisation which profits are not distributed to its shareholders, members, directors, employees or any other persons, and with objectives including, but not limited to, charitable welfare, social service, health and medical care, education, research, trade and industrial alliance, professional advancement, self-help support, etc.The selection criteria for winners in the Individual Director Categories include: successful pursuit of strategic corporate business/non-profit functions, contribution to board effectiveness in strategic planning and monitoring of performance, implementing compliance, risk control and accountability measures, managing change and succession, and leadership and other attributes and qualities, including keen at continuing professional development, business ethics and other achievements. As for the Collective Board Categories, the judging criteria include: board composition, effectiveness in pursuing strategic corporate/non-profit functions, development and execution of strategic plans and monitoring of performance, implementing compliance, risk control and accountability measures, managing change and succession, development of the board, effectiveness of board committees, business ethics and other achievements.The Awards nomination form and related information are available on The Hong Kong Institute of Directors website www.hkiod.com.About Directors Of The Year AwardsLaunched in 2001, the Directors Of The Year Awards was the first of its kind organised in Asia. It is now an annual project of impact in the community. Its objectives are to recognise directors and board of directors for outstanding director practices and corporate governance, to publicise the significance of good corporate governance and to promote awareness of good corporate governance and director professionalism in Hong Kong. Nominations are open to the public. As good corporate governance is vital to all types of organisations, and professional practices from directors in all board roles are encouraged, the Awards recognise excellence in categories by company types, including listed companies, private companies and statutory/non-profit-distributing organisations, and categories by roles, including Executive Directors, Non-Executive Directors and Boards. For more details on the previous years' Awards, please visit http://www.hkiod.com/dya-awardees.html.About The Hong Kong Institute of DirectorsThe Hong Kong Institute of Directors is Hong Kong's premier body representing directors to foster the long-term success of companies through advocacy and standards-setting in corporate governance and professional development for directors. A non-profit-distributing organisation with membership consisting of directors from listed and non-listed companies, HKIoD is committed to providing directors with educational programmes and information service and establishing an influential voice in representing directors. With international perspectives and a multi-cultural environment, HKIoD conducts business in biliteracy and trilingualism. Website: http://www.hkiod.com.Media Enquiries:Strategic Public Relations GroupBrenda Chan +852 2114 4396 brenda.chan@sprg.com.hkChak Yau +852 2114 4395 chak.yau@sprg.com.hkFax: +852 2114 4948Directors Of The Year Awards 2022 Enquiries:The Hong Kong Institute of DirectorsOdessa So +852 2889 4988 odessa.so@hkiod.com Joanne Yam +852 2889 1414 joanne.yam@hkiod.comFax: +852 2889 9982 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

抗疫助稳兴业银行为外贸企业纾困解难

21 6 月, 2022

HONG KONG, Jun 21, 2022 - (亚太商讯 via SEAPRWire.com) - 近日，记者从兴业银行了解到，该行认真落实党中央、国务院关于外贸保稳提质的工作部署，加大跨境融资信贷投放力度，加强跨境人民币业务支持，大力发展外贸新业态金融服务，全力支持外贸企业复工复产和全球展业。今年1-5月，兴业银行跨境人民币收支5123亿元，同比增长158%；跨境融资余额1813亿元，较年初增长24%。“多亏了兴业在线跨境人民币结算绿色通道，原先办理一笔跨境收款的资金解付至少需要半天至一天时间，现在半个小时内搞定，有效缓解了我们经营资金周转难题。”北京一家电子行业头部企业财务负责人感慨道。目前兴业银行北京分行已为该企业办理跨境人民币结算逾100亿元，跨境人民币在线绿色通道，正为国内众多外贸类企业的进出口业务保驾护航。数据显示，1-5月，兴业银行实现本外币跨境结算量1253亿美元，同比增长19%。疫情之下，兴业银行持续完善跨境在线融资体系，近期该行将推出“跨境E贷”在线融资产品，基于数据模型，可实现线上为小微出口企业核定信贷额度和放款，将大幅提升小微企业的融资效率，为出口企业提供便捷、高效、低成本融资服务，助力企业拓展海外市场。外贸新业态新模式是推动我国外贸转型升级和高质量发展的新动能，兴业银行持续推进外贸新业态项下跨境业务发展，服务好跨境电商、海外仓、市场采购贸易、外贸综合服务、新型离岸贸易等领域，打通外贸新业态资金流转链路，为外贸企业保稳提质注入金融活水。以跨境电商为例，兴业银行搭建跨境电商综合服务平台，服务跨境电商进出口企业200多户，前5个月带动跨境结算量7.31亿美元。“兴业银行将加快推进跨境电商综合服务平台升级，加强与跨境电商平台、支付公司等外部平台和机构的合作，构建跨境贸易生态圈，为贸易新业态企业提供全方位金融支持。”兴业银行国际业务部负责人表示。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

ACN Newswire

医思健康订立可持续发展表现挂钩双重贷款开创香港医疗健康市场先河

21 6 月, 2022

HONG KONG, Jun 21, 2022 - (亚太商讯 via SEAPRWire.com) - 香港最大非医院医疗服务机构*──医思健康（「公司」，连同附属公司，总称「集团」；香港联交所股份编号：2138）欣然宣布，集团首次订立可持续发展表现挂钩贷款（「可持续发展贷款」），总值为7亿港元。香港上海汇丰银行有限公司（「汇丰银行」）为是次交易的独家放贷方及可持续发展结构银行。集团是次签署可持续发展表现挂钩双重贷款开创了香港医疗健康服务市场先河，不仅强化了集团行业领导地位，亦证明了可持续发展在集团未来发展策略中的重要地位。是次订立之可持续发展贷款由循环信贷和定期贷款组成，贷款所得额将用作一般企业运营资金。集团致力于将联合国 2030可持续发展目标与业务实践相结合，并针对环境、社会和企业管治 (「ESG」) 各要素制定了一系列明确目标，其中包括减少能源消耗、提高员工对ESG工作的参与度以及对标国际标准提升公司治理水平。香港通用检测认证有限公司为领先的可持续发展顾问服务公司，担任本次订立可持续发展贷款的ESG顾问。医思健康执行董事兼首席策略总监及首席投资总监王家琦女士表示︰「首次订立可持续发展贷款是集团发展的重要里程碑，是集团在可持续发展道路迈出的一大步。作为香港领先的医疗健康服务供应商，是次订立贷款体现了集团将可持续发展纳入其核心业务策略的雄心，以及将最佳优化方案逐步融入集团旗下多元品牌日常营运。我们很高兴能将集团的融资策略与关键ESG绩效指标相结合，体现集团对可持续发展的长期承诺，并为香港医疗健康市场后续的可持续金融交易提供借鉴经验。」关于医思健康香港最大非医院医疗服务供应商*医思健康以预防及精准医疗为业务核心，透过多元服务整合发展医疗人工智慧，配套高端品牌及优质客户服务，致力为客户提供最专业、安全、有效的医疗健康服务。集团为恒生综合指数成份股及MSCI香港小型股指数。集团目前直营的诊所／服务中心主要位于大湾区，提供一站式医疗及健康服务。服务涵盖面极广，旗下主要知名服务品牌包括连续多年荣膺全港第一的一站式医学美容解决方案DR REBORN、专业健发中心发森及多元化多维度的医学服务包括：健康管理中心香港仁和体检中心、疫苗中心香港安苗医疗中心、普通科门诊未来医生、全港最大一站式痛症管理平台纽约脊骨物理治疗中心、全方位牙科服务中心庇利积臣牙科医务所，EC DENTAL CARE及恒健牙科医务所、高端影像中心博思医学诊断中心、仁生肿瘤及癌症中心、内视镜及日间医疗中心仁辉专科中心、专科中心进汇医务中心，联汇专科，新医疗中心、儿科专科汇儿儿科医务中心、妇产科专科卓越医务中心及产前诊断中心、柏立医学化验所、眼科中心唯视眼科和医思兽医医院及影像中心。*根据弗若斯特沙利文公司按2020年及2021年收入计算进行的独立研究若有进一步垂询，请联络：iPR奥美公关刘丽恩 / 陆咏诗 / 叶子欣电话：(852) 2136 6952 / 2169 0467 / 3920 7649传真：(852) 3170 6606电邮：ech@iprogilvy.com Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

ACN Newswire

EC Healthcare Signs Inaugural Dual-Tranche Sustainability-Linked Facility, The First-of-its-Kind in Hong Kong Healthcare Industry

21 6 月, 2022

HONG KONG, Jun 21, 2022 - (ACN Newswire via SEAPRWire.com) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce the signing of its first sustainability-linked facility ("SLL Facility") totalling HK$ 700 million with The Hongkong and Shanghai Banking Corporation Limited ("HSBC") as sole lender and sustainability structuring bank. The inaugural dual-tranche SLL Facility is a first-of-its-kind for a healthcare services provider in Hong Kong, complementing the Group's established status as a leading industry pioneer and reaffirms the importance of sustainability in the Group's future growth strategy. The SLL Facility is comprised of a revolving credit and a term loan, and the proceeds will be used for working capital.The Group is committed to the United Nations 2030 Sustainable Development Goals and has developed a number of clear targets against each of the environmental, social, and governance ("ESG") elements. These include reducing energy consumption, increasing employee engagement, and achieving a globally recognized standard in relation to corporate governance.SGS Hong Kong Limited, a leading sustainability consultancy firm, acted as ESG consultant on the SLL Facility.Ms. Ada Wong, Executive Director, Chief Strategy Officer & Chief Investment Officer of EC Healthcare said, "This maiden sustainability-linked facility is an important milestone and represents another bold step in the Group's sustainability journey. As the leading healthcare and medical services provider in Hong Kong, this transaction reflects the Group's desire to integrate sustainable development into its core business strategy as well as implement best practices into the daily operations of its various brands. We are delighted to align the Group's financing strategy with a number of impactful ESG goals, reinforcing our commitment to sustainability in the long-term. We are excited to set the stage for subsequent sustainable finance transactions in the Hong Kong healthcare market."About EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of the Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, a professional hair care center HAIR FOREST, primary care clinics jointly established with health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, General outpatient clinic Tencent Doctorwork, the largest one-stop pain management centre in Hong Kong New York Medical Group, the comprehensive dental centres Bayley & Jackson Dental Surgeons, EC DENTAL CARE and Health and Care Dental Clinic, an advanced diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic PREMIER MEDICAL CENTRE, SPECIALISTS CENTRAL and NEW MEDICAL CENTER, a paediatric centre PRIME CARE, a gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, PathLab Medical Laboratories, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 2021For further information, please contact: iPR Ogilvy Limited Callis Lau / Lorraine Luk / Charmaine Ip Tel: (852) 2136 6952 / 2169 0467 / 3920 7649 Fax: (852) 3170 6606 Email: ech@iprogilvy.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

Ev Dynamics is Commissioned to Build Hong Kong’s First Accessible Electric Bus

20 6 月, 2022

HONG KONG, Jun 20, 2022 - (ACN Newswire via SEAPRWire.com) - Ev Dynamics (Holdings) Limited (the "Company", Stock Code: 476, together with its subsidiaries, collectively "Ev Dynamics" or the "Group"), a provider of new energy vehicles and integrated technology solutions, has received another purchase order from the Hong Kong Productivity Council to deliver a pure electric bus for use by a Hong Kong non-governmental organisation ("NGO"), which follows the Council's earlier order of electric buses for the Airport Authority Hong Kong and the Hong Kong Anti-Cancer Society.Ev Dynamics' pure electric bus is powered by sustainable high energy density batteries and is designed to adapt to and manoeuvre through complicated city road systems.The bus is equipped with an extra-low platform for easy accessibility for seniors and those with impaired mobility. It has enough space to house up to 33 regular seats and two wheelchairs.Developed by the Group under a new purchase agreement with the Hong Kong Productivity Council, the electric bus boasts a light aluminium alloy body structure with a highly efficient traction motor system, complemented by a full load-bearing electric bus chassis, high energy density batteries that ensure extended stable power output, and other innovative technological features. Moreover, the vehicle is set to be the first socially inclusive electric bus in Hong Kong, having been specifically designed to be accessible to seniors and those with disabilities, with features such as an extra-low platform for easy accessibility and enough space to house up to 33 regular seats and two wheelchairs. It also boasts the unique advantages of a relatively low weight and low energy consumption, making it a cost-efficient and sustainable transport solution. Subject to type approval, inspection and registration granted by the Transport Department, the Group expects delivery to be completed together with an EV charger installation project located next to the NGO's service centre in Tai Po by the end of next year, and will continue to provide quality after-sales maintenance and repair services to the end-user NGO.Miguel Valldecabres Polop, CEO of Ev Dynamics said, "We are always proud and excited when our products are brought to the public. In the past year, we have been expanding our global reach in the international electric vehicle market, especially in high-growth areas such as Europe, Latin America and Asia, but we are especially honoured to have received an order from our home market of Hong Kong. The pure electric bus showcases the Group's most innovative technological and product advantages, boasting zero emissions, reliable operation and sustainable design systems that will help to realise green targets related to the reduction of roadside air and noise pollution. The bus is also designed to be accessible to all members of society, including seniors and those with impaired mobility who may face obstacles when riding public transportation on a regular basis. We expect it to set the standard for energy efficient public transport, as the future of transport lies in electromobility, as well as further Ev Dynamics' market expansion in the local market." About Ev Dynamics (Holdings) Limited (Stock Code: 476)Ev Dynamics (Holdings) Limited is a pioneer and prominent player in China's new energy commercial vehicles market, as well as a whole-vehicle manufacturer of specialty passenger vehicles and new energy passenger vehicles. It is an integrated driving and logistics solutions provider with a solid technological foundation in diverse areas including new energy platform power systems and their key components. The Group has a production base in Chongqing, boasts extensive domestic and overseas sales networks, and focuses on serving high-growth markets in Southeast Asia, Europe and Latin America.Media EnquiriesStrategic Financial Relations LimitedVicky Lee +852 2864 4834 vicky.lee@sprg.com.hk Phoebe Leung +852 2114 4172 phoebe.leung@sprg.com.hkBrigid Lee +852 2114 4313 brigid.lee@sprg.com.hkWebsite: www.sprg.com.hk Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

科轩动力获委托建造香港首辆无障碍电动巴士

20 6 月, 2022

HONG KONG, Jun 20, 2022 - (亚太商讯 via SEAPRWire.com) - 新能源汽车及技术综合解决方案供应商科轩动力（控股）有限公司（「公司」；股份代号：476，连同其附属公司，统称「科轩动力」或「集团」）再次接获香港生产力促进局采购订单，交付一辆纯电动巴士供一个香港非政府机构（「非政府机构」）使用。香港生产力促进局较早前已为香港机场管理局及香港防癌会向集团采购电动巴士。科轩动力的纯电动巴士采用可持续的高能量密度电池，能灵活穿梭于复杂的城市道路系统。超低地台设计方便长者和残疾人士上落，并提供足够空间容纳多达33个标准座位和两台轮椅。该辆电动巴士根据集团与香港生产力促进局的新采购协议而开发，采用轻身的铝合金车身结构和高效的牵引动力系统，配以全承重式电动巴士专用底盘、高能量密度电池确保功率输出长期稳定、以及其他创新科技特点。此外，该车辆将成为香港首款社会共融电动巴士，其超低地台等特别设计方便长者和残疾人士上落，并提供足够空间容纳多达33个标准座位和两台轮椅。该车辆的其他独有优势还包括较轻巧和低能耗，让其成为具成本效益和可持续的运输解决方案。待运输署发出类型审核、检验及登记后，集团预计将于明年年底前连同位于大埔非政府机构服务中心旁的电动车充电站安装项目完成交付。集团将继续为该终端用户非政府机构提供优质的售后保养和维修服务。科轩动力行政总裁Miguel Valldecabres Polop表示：「我们对产品面世深感自豪，也非常雀跃。在过去一年，我们一直在扩大国际电动汽车市场的覆盖，尤其是欧洲、拉丁美洲和亚洲等高增长地区，但我们对收到香港本地市场订单感到特别荣幸。该纯电动巴士展示了集团最新技术和产品优势，其零排放、运作可靠和可持续设计系统有助实现与减少路边空气和噪音污染相关的绿色目标。该巴士的设计方便社会各界人士使用，包括乘坐公共交通工具时有困难的长者及行动不便人士。电动汽车就是交通的未来，我们预计该车辆将会成为节能公共交通的标准，并帮助科轩动力在香港本地市场进一步扩张。」关于科轩动力（控股）有限公司（股份代号：476）科轩动力（控股）有限公司为新能源商用车的先行者和实践者、专用客车和新能源客车整车生产商，在新能源平台化电系统及关键零部件方面有着坚实的技术基础，是出行与物流综合解决方案的供应商。集团在重庆设有生产基地，拥有广泛的海内外销售网路，及重点开拓东南亚、欧洲和拉丁美洲的高增长市场。新闻垂询纵横财经公关顾问有限公司李惠儿 +852 2864 4834 vicky.lee@sprg.com.hk 梁家仪 +852 2114 4172 phoebe.leung@sprg.com.hk 李溢晴 +852 2114 4313 brigid.lee@sprg.com.hk 网址：www.sprg.com.hk Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

玄武云科技拟赴港上市：聚焦智慧CRM服务抢占AI、SaaS风口

20 6 月, 2022

HONG KONG, Jun 20, 2022 - (亚太商讯 via SEAPRWire.com) - 据彭博终端机报道，近年来，数字化浪潮席卷各行各业，在大数据、AI、SaaS等技术服务加速渗透的背景下，智慧CRM服务市场快速增长。根据弗若斯特沙利文资料，2017年至2021年，中国的智慧CRM服务市场TAM由人民币251亿元增至人民币718亿元，复合年增长率为30.1%，预计于2026年将增至人民币2,800亿元，自2021年起的复合年增长率为31.3%，市场想象空间十分巨大。为抓住行业发展契机，通过资本市场的力量不断壮大规模和实力，国内最大的智慧CRM服务供应商——玄武云科技控股有限公司（以下简称「玄武云科技」）于近日通过聆讯，拟在港交所主板上市，招银国际为独家保荐人。据了解，玄武云科技是智慧CRM服务行业的领先企业，通过云和全触点通信、人工智能及数据智能等方式，为企业提供综合智慧CRM服务，覆盖其客户全渠道及全生命周期。根据弗若斯特沙利文报告，按收益计，玄武云科技是中国国内最大的智慧CRM服务供应商。全面且多样化的服务矩阵在竞争对手中脱颖而出自成立以来，经过多年的积累，玄武云科技已具备完善的产品体系，积累了丰富的行业经验。该公司的综合智慧CRM服务基于云和全触点通信、人工智能及数据智能能力，分为CRM PaaS服务及CRM SaaS服务两类。CRM SaaS服务由营销云、销售云及客服云组成，将传统CRM功能与云、经升级及封装的通信能力以及人工智能及数据智能能力整合，为客户提供从前端营销到售后服务的全生命周期的一站式智慧CRM服务。玄武云科技的CRM PaaS及CRM SaaS服务，可帮助其客户以更为高效的方式管理，包括产品展示、订单履行、全渠道营销、会员计划管理以及业务分析及报告。这些服务能够满足广大客户在公有云、私有云及混合云方面的不同需求，并通过开发新服务及增强现有服务，向客户提供完善的服务体系，满足不同客户需求，持续巩固自身领先地位。全面且多样化的服务矩阵，令玄武云科技不断扩张业务类型及服务区域，营收实现稳步提升。财报数据显示，2019-2021年，营收分别约为人民币（下同）6.00亿元、7.97亿元、9.92亿元，复合年增长率为28.6%。同期，毛利分别约为1.97亿元、1.94亿元和2.32亿元，盈利水平稳中有升。据招股书披露，未来，公司将透过持续在主要行业深耕及垂直领域扩张来发展及扩大公司的客户群，同时，进一步加大研发投入，提升技术创新能力，加强及扩展公司的CRM SaaS服务，并持续调整客户结构，以提升毛利率，不断增强核心竞争力，推动公司长期高质量发展。高度可扩展的业务模式客户数目及贡献稳步上升除了全面的产品，玄武云科技还拥有高度可扩展的业务模式。基于强大云基础架构的综合智慧CRM服务，该业务模式能够捕捉在客户业务发展中出现的各类需求，从而获得更多交叉销售机会。根据招股书数据，2018年，玄武云科技的客户中有306名购买一种以上服务（即cPaaS、营销云、销售云或客服云），占同年客户总数的11.8%，而在2021年，这一数据为345名，占同年客户的13.1%，客户群稳定增长。此外，玄武云科技还能在同一行业的新客户中快速扩展其业务，经过在各个行业长达十年的深耕，其优质客户群涵盖了包括快消品、金融、TMT及政企等高增长行业的领先企业，具有绝对的先发优势。就快消品行业而言，于2021年，分别覆盖食品及饮料分部百强企业中的28家及24家，以及日用品及白酒分部百强企业中的20 家及10家。就金融行业而言，于2021年，分别覆盖了银行分部百强企业中的37 家和138 家受监管证券公司中的30 家。就TMT行业而言，于2021 年，分别覆盖了互联网及软件分部百强企业中的21 家及15 家。强大产品开发及技术能力实现长期业务扩张研发是科技企业之魂，也是企业的核心竞争力。近年来，玄武云科技根据客户的独特行业需求，开发及推出适合客户需求的解决方案，打造差异化的服务。自主开发的aPaaS平台（一种低代码开发平台），支持该公司可根据客户的个性化需求，对解决方案进行定制化的应用开发，同时又可通过aPaaS平台，节省开发成本，并在开发过程中获得更可靠的质量。此外，公司开发了基于机器学习、深度学习、图像分割及光学字符识别（「OCR」）的计算机视觉相关人工智能识别引擎，以及基于数据智能的智能决策算法（即自动售货机内安装的人工智能摄像头所使用者），使公司能够每天处理逾1,000个人工智能识别及数据智能决策项目。通过先进技术的应用，公司能为客户提供稳定可靠的智慧CRM服务，使客户能够节省大量的人力成本，提高沟通效率，提升用户体验及管理及运营效率。截至目前，玄武云科技已拥有199项与人工智能、数据智能和其他智慧CRM服务相关的注册发明专利及计算机软件版权，该公司的综合联属实体之一——玄武科技已获颁「国家高新技术企业证书」。强大的研发创新能力令其在众多竞争者中脱颖而出，并获得客户、行业及政府的相关肯定及认可。作为国内领先的智慧CRM服务提供商，玄武云科技除了能够为客户提供全触点、全渠道、全生命周期的智慧CRM服务外，还基于强大的产品开发能力及交叉销售能力，捕捉客户在业务发展中出现新的需求从而完成更多的产品销售并提高客单价。此外，通过为客户提供差异化产品，不断提高下游客户的用户粘性以及付费意愿。高度可扩展的业务模式，将有利于该公司通过行业客户的标杆经验和业务模型，复制扩展到中腰部企业，进而实现长期业务扩张。长期来看，智慧CRM服务供应商有效解决了传统CRM服务的痛点，正在颠覆传统CRM市场，整个行业有着广阔的发展空间。根据弗若斯特沙利文资料，智慧CRM服务市场的总收益由2018年的人民币16亿元增至2021年的人民币72亿元。未来，预期智慧CRM服务市场的总收益将于2026年增至约人民币368亿元，自2021年起的复合年增长率约为38.6%。由于下游行业对提高服务质量及综合智慧CRM服务的强烈需求，在政策支持下，玄武云科技将受益于中国智慧CRM服务行业的强劲增长。总体而言，智慧CRM服务行业前景广阔，香港IPO将是玄武云科技发展史上的又一里程碑，未来，在资本市场的加持之下，其构筑的服务及技术壁垒将得到巩固，核心竞争力进一步提升，市场份额也有望扩大，成长空间值得期待。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

ACN Newswire

王朝酒业2022年产品升级以更时尚、年轻化新品激发品牌活力

20 6 月, 2022

HONG KONG, Jun 20, 2022 - (亚太商讯 via SEAPRWire.com) - 中国优质葡萄酒生产商王朝酒业集团有限公司(「王朝」或「集团」)(股份代号：00828) 进行2022年产品升级，推出革新小容量373毫升及180毫升螺旋盖产品、「怡色」系列礼盒包装以及国风版系列，为消费者带来更时尚、年轻化的新品，抢占年轻消费者市场。革新小容量373毫升及180毫升螺旋盖产品「怡色」系列礼盒版包装汉字版「王朝」字样的国风版系列新品集团推出颠覆传统葡萄酒市场的小容量373毫升及180毫升王朝老干红葡萄酒及半干白葡萄酒，以创新小瓶装设计打入年轻消费者市场。相比集团传统葡萄酒的750毫升容量，新产品采用螺旋盖设计，提供更加便捷的品尝途径，更适宜年轻人随时随地即兴喝葡萄酒。当中，180毫升系列以一盒六瓶的包装亮相，剑指啤酒市场，为年轻人聚会畅饮提供另一选择。此外，373毫升系列更增加赋能功能，通过与O2O平台结合，消费者扫描二维码后即可获得奖赏，既能提升消费者与品牌的互动，又能把实惠和惊喜直接带给消费者，把王朝产品推广给更广泛的消费者人群。王朝针对年轻消费者的入门级价位产品「怡色」系列葡萄酒去年推出后反应热烈，今年在原有产品的基础上增加了礼盒版包装，为亲朋好友聚会及佳节喜庆提供最佳送礼选择。「怡色」系列聚焦年轻消费群体的即饮渠道，可配搭火锅、融合菜式、私房菜等年轻人喜欢的菜式，因此深受年轻人喜爱。加上结合小红书、抖音、快手、微博等新媒体营销，「怡色」系列成功晋身为网络上的爆红产品。王朝产品一直以「DYNASTY」品牌展示，为进一步加强王朝品牌认知度，特别推出以汉字版「王朝」字样为主元素的国风版系列，更能突显王朝作为国产葡萄酒品牌，顺应国潮风，吸引追求国货、国潮的电商主流消费群体。王朝计划在电商全渠道推广国风版系列，除了已于主流电商平台推出外，亦会采用直播、视频等辅助推广方式，深耕新零售渠道。王朝近年积极求新，聚焦「5+4+N产品战略」，其中「N」代表集团推出N项需求定制，不断开拓创新产品，以满足中国不同类型消费群体的多元化需求。王朝通过2022年产品升级推出更便捷品尝、更年轻化以及顺应国潮风的新品，可激发品牌活力，加强面向年轻消费者的产品布局，并巩固王朝作为国产葡萄酒代表的品牌形象。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

直播带货潮国美零售（493.HK）618销售额值得期待

17 6 月, 2022

HONG KONG, Jun 17, 2022 - (亚太商讯 via SEAPRWire.com) - 昨日港股活跃，恒指高开200多点，随后开始走弱，昨日收报20845点, 跌462点, 成交量为1584亿元。大盘及新经济等多个板块走弱，而新东方转型的“东方甄选”直播带货引发热点带动教育及电商相关板块逆市增长，留意到国美零售（493.HK）昨日盘中大涨，最高至0.53元，涨幅达41.3%，收盘价涨25.3%报0.47元。受惠于内地家电补贴政策，促进家电更新与夏日带来的新增需求的释放，该市场有望回暖，国美零售亦因此受益。公司拥有数十年的零售经验，并顺势战略调整，旨在构建“线上+线下+供应链+物流+大数据云+共享共建”全零售生态共享平台，以满足家庭消费者高质量、多元化、一站式的全方位需求。作为零售巨头，国美零售的优势一方面在于积淀，统一的供应链体系优于独立经营，规模采购下的产品成本控制，同时拥有遍布中国的近4200家门店，其中包括230多家体验店、1200多家小区店和2700多家新零售店。另一方面，随着消费者网购习惯的形成，线下门店网络已全面数字化，国美在线平台“真快乐APP”实现了门店的在线平移，使得每个门店可服务周边3-5公里的国美社群用户。2021年报显示APP每月活跃用户(MAU)稳定在5,000万以上。而真快乐APP不仅是零售平台，是娱乐化营销，同时兼具社交化和娱乐化，吸引不少明星艺人KOL入驻，兼具抢购商品、直播带货、视频导购等功能。数据显示，“618”活动第一波在6月1日至5日期间，真快乐APP销售额环比5月同期增长接近10％，线下门店总销售额突破5亿元。而目前“618”第二波活动正在如火如荼进行，网购热潮连带各大厂商给予的巨大优惠力度，国美零售有望迎接亮眼的销售额，后市可持续关注。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

ACN Newswire

兴业银行：助企纾困出实招稳住经济基本盘

15 6 月, 2022

HONG KONG, Jun 15, 2022 - (亚太商讯 via SEAPRWire.com) - 今年以来，兴业银行坚持稳字当头、稳中求进，聚焦重点领域、薄弱环节，持续加大实体经济金融支持，通过拓宽融资渠道、开辟绿色审批通道、下调贷款利率、减费让利等方式综合施策，打通融资“阻梗塞”，拓宽企业“融资路”，为稳住经济大盘贡献兴业力量。截至5月末，兴业银行以企业客户为主的对公贷款余额2.35万亿元，较年初新增1950多亿元。兴业银行杭州分行针对物流企业特点，陆续推出无还本续贷、纯信用贷款等一系列服务方案，保障物流企业的日常运营。兴业租赁支持5家唐山市物流公司采购125台新能源重卡，保障运输“生命线”皇宝（石狮）实业有限公司生产车间辽宁省农药有限公司在为春耕集中备货四川飞亚动力科技股份有限公司生产车间打通“阻梗塞” 为物流畅通“加油”货运物流关系百姓生活，关系国民经济的发展和产业链的循环。今年以来疫情呈现多点散发、反复多变的态势，部分货运物流企业的正常经营受到巨大冲击。杭州乾元物流有限公司是“饿了么”的配送加盟商，拥有日处理“饿了么”配送5万单的能力。随着4月份杭州疫情的持续升级，封闭区逐渐增加，但公司运力不减，“骑士”们始终穿梭在城市的大街小巷，满足千家万户的物资需求。疫情期间，企业资金需求大，且在兴业银行的贷款即将到期。得知这一情况后，兴业银行开通绿色通道，为企业办理260万元无本续贷的“连连贷”业务，解除了企业的后顾之忧。无锡睿航物流公司也是兴业银行“连连贷”的受益者，在150万续贷资金支持下，短时间内还贷资金和流动资金双重压力迎刃而解。据悉，疫情期间，兴业银行持续加大对货运物流循环畅通的金融支持力度，对承担疫情防控和应急运输任务较重的运输物流企业开辟“绿色通道”，优化信贷审批流程，提供灵活便捷金融服务，对于因疫情影响偿还贷款暂时困难的运输物流企业，给予贷款展期和续贷安排，帮助货运物流行业纾困解难，以金融之力为物流畅通“加油”，保障供应链产业链安全。“疫情反复让我们经营压力倍增，借助兴业银行数字供应链产品，我们成功获得300多万元的贷款额度,让我们面对疫情更加从容！”一家唯品会合作企业负责人表示。兴业银行持续完善数字供应链金融产品服务体系，与福州朴朴和广州唯品会等生鲜类及服装类电商平台合作，通过兴享供应链平台与电商供应链平台创新融合，“一户一策”为电商平台上游供应商提供量身定制的一站式供应链金融服务，有效解决了疫情期间民生保供平台上游供应商的临时性资金需求，持续提升融资便捷性和可得性。运输车辆是物流畅通的生力军，兴业银行发挥综合经营优势，与旗下兴业租赁公司协同联动，为物流企业采购新能源重卡提供租赁资金支持，保障运输“生命线”。唐山港地处环渤海经济带核心地区，承担着环渤海地区钢铁、煤炭、汽车等工业大宗商品的吞吐任务。疫情期间，唐山港区大宗商品运输需全力保障，当地多个物流公司提出增购新能源重卡需求，急需金融支持。兴业银行全资子公司兴业金融租赁利用自主开发的普惠金融科技系统，在不足十天时间内，以融资租赁形式支持5家唐山市物流公司采购125台新能源重卡，采购金额8200多万元，当月即投入到唐山港区运输保供队伍中。普惠支小支农稳住经济“底盘” 温州和喜和贸易有限公司是一家从事花岗岩、玄武岩等碎石建材的传统贸易型小微企业。因2022年春季疫情在长三角区域突发，企业外输物流受到冲击，大量石材囤积港口无法及时运输至下游客户，企业回款时间不断被延后，面对即将到期的100万元贷款犯了难。兴业银行温州分行得知情况后，主动与企业负责人沟通了解情况，为企业延长贷款六个月，全力帮助企业渡过难关。小微企业背后是千千万万的家庭和就业，是稳经济的基本盘。兴业银行针对小微企业等受困市场主体，强调不得盲目限贷、抽贷、断贷，通过提供中长期贷款、降低利率、展期或续贷支持等方式，不断提升小微企业融资便利度和可得性。同时，积极探索数字化金融服务新模式，努力实现小微企业贷款“增量、扩面、降价、提质”，为保市场主体注入更多金融活水。“早上到公司了解情况，下午就放款了，效率真是高！”在收到兴业银行泉州分行发放的970万元制造业企业贴息贷款后，皇宝（石狮）实业有限公司负责人欣喜地说。皇宝实业是一家从事漂染的高新技术制造企业，受疫情影响，该公司销售货款回笼较慢，急需资金用于稳定生产经营。兴业银行泉州分行在开展支持复工复产专项走访中了解到企业的情况后，立即协助企业通过福建金服云平台开设的“制造业中小微企业融资支持专项”专区申请办理，并于当天顺利放款，大大节省了企业成本。作为平台建设运营方，兴业银行依托福建金服云平台，将大数据持续转化为生产力，广引金融活水，为中小微企业提供更加便捷、精准的金融服务，截至目前，已解决中小微企业融资需求突破1500亿元，解决了36000家企业和个体工商户43800多笔贷款资金的燃眉之急。同时该行还充分利用互联网和大数据技术，开发了具有“线上申请、线上审批、线上放款、随借随还”特点的“快易贷”“合同贷”“e票贷”等线上融资产品，为政府采购、供应链上下游、银税互动等不同场景下的小微企业提供全流程的线上融资服务。在服务小微企业的同时，兴业银行聚焦粮食安全，围绕春耕备耕、粮食流通收储加工等全产业链，制定差异化信贷支持措施，加大对涉农主体的支持力度，为农业生产送来普惠“及时雨”。截至4月末，兴业银行涉农贷款余额5172亿元，较年初增加509亿元，增速10.9%。5月份，河南省8500万亩小麦陆续成熟并进入收获期，一派丰收景象丰收在望。在新乡辉县，由于去年遭受水灾比较严重，小麦播种比往年播种要晚，但农户们比往年更加渴望丰收。兴业银行新乡分行迅速开辟绿色通道，3天内为辉县市金穗粮油有限责任公司完成1000万元“粮储贷”的放款，确保颗粒归仓，农民“粮出手”“钱到手”。在东北粮仓辽宁，严峻的疫情，给辽宁省农药有限公司集中备货工作造成不小的挑战，如不及时解决资金问题，将直接影响当地的春耕进度。借助绿色审批通道，兴业银行沈阳分行迅速向企业发放了5000万元贷款，极大缓解了企业的备货困扰和资金周转压力，有效保障疫情防控期间春耕农资产品数量足、价格稳，为守护东北大粮仓贡献金融力量。拓宽融资“高速路” 降低企业“负荷量”在帮助企业纾困过程中，兴业银行在对企业加大信贷支持的同时，还创新融资方法，“商行+投行”拓宽企业融资的高速路，并通过减费让利等举措，降低企业负荷，让企业轻装上阵。四川飞亚动力科技股份有限公司是一家汽车零部件制造商，是国家级“专精特新”小巨人企业。日前，为满足该企业日常经营周转资金需求，兴业银行应用“技术流”体系，给予该公司信用免担保授信额度1000万元，有效满足了公司的融资需求，支持该公司持续发展壮大。相对于传统以企业财务状况为依据的“资金流”评价体系，“技术流”评价体系涵盖8个一级指标、17个二级指标，着重考察企业科技创新能力，并根据指标分值，给予企业技术流评级，破除了科创企业的融资难题。截至5月末，兴业银行通过“技术流”评价体系累计向企业投放资金余额726亿元。青岛航大新材料技术有限公司凭借国际领先的自主知识产权实现产学研的有机融合，并于2017年正式投入汽车轻量化材料的生产，近两年来稳步推进环保生产转型，并阶段性停产转移生产基地，让这家初创期企业资金面雪上加霜。兴业银行青岛分行深入调研后，发现企业在企业供应链中具有核心竞争优势，市场前景广阔，为企业量身设计了以私募股权基金投资为依据的“投联贷”专属服务方案，于今年5月末完成全部1000万元放款，并提供优惠利率，极大缓解了企业融资难题。让企业跑起来，拓宽融资“高速路”的同时，必须降低企业负荷量。兴业银行围绕企业减费让利出台一系列政策，持续加大减费让利力度，为市场主体纾困减负，帮助其渡过难关，恢复发展。4月份，兴业银行新发放普惠小微企业贷款加权平均利率较2020年12月下降47BP。为进一步加大减费让利力度，该行在贯彻落实人民银行等四部委发布的《关于降低小微企业和个体工商户支付手续费的通知》要求基础上，自主加大减费让利力度，自2022年4月30日起，将对公账户/收支控制费、账户信息查询费、组合签章管理费等8个收费细项调整为免费，还适当下调部分与客户日常基础结算相关的项目收费标准，主动降低企业负担。仅今年一季度，该行服务收费减免金额约19亿元。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

市场首批科创票据花落兴业银行

15 6 月, 2022

HONG KONG, Jun 15, 2022 - (亚太商讯 via SEAPRWire.com) - 6月14日，兴业银行主承销的市场首批用途类科创票据成功发行，为象屿集团募集资金10亿元，专项用于厦门天马显示科技有限公司建设第六代柔性主动矩阵有机发光二极体（AMOLED）项目生产线项目，该项目为国内最大的柔性AMOLEO单体工厂。此前，兴业银行已于6月初主承销落地市场首批2单主体类科创票据，为中交第二航务工程局有限公司、云南省建设投资控股集团有限公司合计募集资金15亿元，支持科技创新引领产业升级。“科创票据精准支持了科创领域企业融资需求，进一步拓宽了债券支持实体经济路径，为科创领域提供了低成本直达资金，有效助力资本市场服务国家创新驱动发展战略。”兴业银行投资银行部总经理林舒表示。据了解，5月20日，交易商协会整合高成长型企业债务融资工具、双创专项债务融资工具和创投企业债务融资工具三大科技创新主题融资产品工具箱，升级推出科创票据，支持科创企业发债用于生产经营，非科创企业发债用于科创领域的股权投资、基金出资、项目建设等，引导资金向科技创新领域集聚，助力加快建设科技强国。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

力保市场主体兴业银行零售普惠小微贷款余额超2200亿元

15 6 月, 2022

HONG KONG, Jun 15, 2022 - (亚太商讯 via SEAPRWire.com) - “今年的樱桃收购，我们心里特别有底气，兴业银行为我们在线发放了200万元信用贷款，帮了我们樱桃果农的大忙。”大连金普新区大莲泡村的樱桃大棚里，大连一家果业集团工作人员正在忙碌收购果农刚采摘的樱桃，正是这笔贷款，让该果业集团有充足资金在各村设立收购点，也让果农不再为樱桃的销路担忧。3月以来，受新一轮疫情影响，很多小微企业、个体工商户经营受困。兴业银行心系实体，风雨同舟，坚决贯彻党中央国务院决策部署要求，以自身零售信贷体制机制改革为契机，着力完善“敢贷、愿贷、能贷、会贷”长效机制，全面提升小微企业及个体工商户零售信贷的可得性、覆盖面与便利度。截至2022年4月末，兴业银行零售普惠型小微贷款余额超2200亿元，较年初增长11%，当年个人经营贷发放逾700亿元，为“保市场主体保就业保民生”输送源源不断的金融活水。健全机制确保敢贷愿贷实现普惠金融可持续发展，离不开体制机制保障。今年以来，兴业银行启动实施包括零售条线等在内的体制改革，在总行层面成立一级部门零售信贷部，进一步深化零售信贷业务集约化经营，建立更加敏捷高效的零售信贷工厂，提升普惠金融服务水平。在制度层面，该行出台《兴业银行零售小微贷款业务尽职免责实施细则》，明确零售小微企业贷款业务尽职免责的认定标准、免责范围等，进一步激发基层服务小微企业的内生动力。同时全面加快数字化转型，持续推进“天网工程”建设，以“数据+模型+系统+场景”为切入点，打造开放共享、数据驱动、模型探索、敏捷运维的零售智能风控中台，目前一期工程已上线，实现了全集团自然人风险数据的整合、共享与分层,支持对零售信贷风险的全方位扫描，全面提高了贷前、贷中、贷后风险甄别和预警能力，为高质量开展零售信贷业务保驾护航。创新产品夯实能贷基础兴业银行鼓励各分行结合当地特色产业开展个人经营贷业务，形成“一行一策、一户一策”的贷款解决方案，为不同行业、不同经营群体提供融资支持，力争做到“哪里有需求，哪里就主动对接服务”。快经贷、商车贷、产业园区贷、创业贷、光伏贷……截至2022年4月末，兴业银行共计落地逾200个“兴惠贷”特色服务专案，覆盖全国200多个城市，有效满足小微企业资金周转需求，为地方经济注入生机与活力。为满足客户对贷款时效性、便捷性的要求，兴业银行还自研创设了消费兴闪贷、经营兴闪贷等全线上化个贷产品，并推出了针对存量经营贷客户无还本续贷的产品“连连贷”，针对房贷客户先还利息、暂缓还本金的产品“随薪供”等特色产品，灵活满足客户差异化需求，精准匹配最合适的产品。科技赋能提升会贷能力兴业银行不断强化科技赋能，加快推动零售信贷向“个性化、便利化、智能化”升级。部分业务可实现当天放款，有的信用类贷款可实现秒级审批放款。例如，该行推出的个贷数字化应用项目之一“兴通途”可以实现个贷从进件、审批到放款全线上操作，客户通过“个贷工作室”“二维码收件”等线上功能即可实现贷款在线申请，服务体验大大提升。与此同时，兴业银行“兴智汇”APP线上审批功能可实现审批人员在移动端处理业务，让常在外跑业务的客户经理也可不受地理限制，随时随地移动办公。“不管是我们自己处理业务，还是帮客户查询审批进度，都非常方便。”基层的客户经理们纷纷点赞。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

ACN Newswire

万隆、雅各臣及健倍苗苗成立合资公司拓展大中华区及亚洲专科药及品牌医疗保健市场

15 6 月, 2022

HONG KONG, Jun 15, 2022 - (亚太商讯 via SEAPRWire.com) - 万隆控股集团有限公司（「万隆」，连同其附属公司「万隆集团」; 股份代号：0030.HK），其控股股东为云南白药集团股份有限公司（证券代号000538.SHE）、雅各臣科研制药有限公司（「雅各臣」，连同其附属公司（不包括健倍苗苗集团）统称「雅各臣集团」；股份代号：2633.HK）及健倍苗苗（保健）有限公司（「健倍苗苗」，连同其附属公司统称「健倍苗苗集团」；股份代号：2161.HK）今天联合宣布成立万隆雅健药业有限公司（「合资公司」），以把握大中华区及亚太地区专科药及品牌医疗保健市场的增长机遇。后排：由左至右：万隆行政总裁汤明先生及雅各臣执行董事及健倍苗苗非执行董事严振亮先生见证签约仪式；前排：由左至右：万隆执行董事及副行政总裁刘周阳先生及雅各臣首席财务官余振球先生签署合资公司协议合资公司由万隆、雅各臣及健倍苗苗分别拥有60%、20%及20%权益，将主要从事获取专科药（包括罕见病用药）、非处方药、品牌医疗保健品（包括草药产品）及医疗器械的授权，以及于大中华区及亚洲地区之经选定市场销售及分销该等产品，并发掘战略性合适的并购机会。凭借三家公司各自的市场知识、能力及网络，合资公司旨在于上述地区的高增长专科药物、品牌医疗保健品及医疗器械市场建立稳固的据点并实现实质商机。万隆行政总裁汤明先生表示：「大中华区及亚太地区的医药、医疗保健及医疗器械市场的前景秀丽，加上後疫情時代下個人醫療保健意識日漸提高，為合資公司提供了巨大的市場潛力。从数据上来看，内地医药和医疗保健市场未来数年的年均增长率超过9％，增长十分强劲。我们很高兴与雅各臣和健倍苗苗建立战略合作伙伴关系，以扩大我们的医疗保健贸易产品组合，并利用我们的协同优势抓住及实现市场机遇。」雅各臣執行董事嚴振亮先生表示：「我们很高兴与万隆强强连手。并期望通过合资公司加强我们在大中华区及亚洲市场的据点。这次合作与我们市场扩展之策略不谋而合，合资公司将促进及加强我们于该等地区之专科药、品牌医疗保健品和医疗器械市场的准入，并透过合资平台为合作伙伴缔造交叉销售协同效应。」关于万隆控股集团有限公司（股份代号：0030）万隆控股集团有限公司为一间国际化的医疗保健产品贸易公司，业务遍及大中华地区及主要亚洲市场（包括日本、韩国及东盟国家），作为美国、瑞士及其他欧盟企业的品牌产品认可总代理，万隆的产品组合拥有广泛的精选医疗保健产品。有关万隆的更多详情，请浏览集团网站：http://0030.com.hk关于雅各臣科研制药有限公司（股份代号：2633）雅各臣是本地领先的医药公司，拥有垂直整合的业务，包括基础药物及专科药物的研发、生产、分销、销售及物流。作为本地主要的非专利药供货商，集团在香港私营及公营领域，具有最广泛的销售及分销的市场覆盖，并积极向策略性选择的亚洲市场伸延扩展。集团于香港设有10间PIC/S GMP认证的非专利药生产设施，并在各种治疗药物类别中拥有广泛的产品组合与享有优越市场地位。同时，集团一直致力透过增加各种高增值产品，策略性地扩大其非专利药的产品组合。扎根香港，集团已于中国、澳门、台湾、新加坡及柬埔寨开设营运子公司，建立区域性商业平台，以把握亚太区及大中华地区的市场潜力。而自 2017 年 6月 1 日，集团获纳入 MSCI 香港微型股指数成份股。更多详情请浏览雅各臣科研制药有限公司网站：http://www.jacobsonpharma.com/有关健倍苗苗（保健）有限公司（股份代号：2161）健倍苗苗是设于香港的品牌医疗保健品推广及分销公司，产品据点遍及大中华、东南亚及其他选定国家。集团拥有丰富的营销专业知识并具备深厚的制药背景，秉承产品功效和质量至上的优良传统，在行业内定位独特，致力于满足消费者的保健需要。作为本地领先的品牌医疗保健品运营商，集团拥有一广泛系列品牌医疗保健品，包括品牌药、品牌中药及健康护理产品，其中包括「保济丸」、「何济公止痛退热散」、「德国秀碧除疤膏」、「德国宝宝手指水」、「美德玛宝儿除疤膏」、「唐太宗活络油」、「飞鹰活络油」及「十灵丹」等家喻户晓的传统品牌。有关集团详情，请浏览： www.jbmhealthcare.com.hk Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

ACN Newswire

10 winning start-ups stand out at Start-up Express

15 6 月, 2022

HONG KONG, Jun 15, 2022 - (ACN Newswire via SEAPRWire.com) - The fifth edition of Start-up Express, an entrepreneurship development programme organised by the Hong Kong Trade Development Council (HKTDC), came to a successful conclusion today. The Pitching Final, which was streamed live, saw 10 winning start-ups selected from a total of 20 shortlisted companies. The "My Favourite Start-up Award", decided through live online polling, was awarded to Good Food Technologies, while the newly added ESG Award went to i2Cool in recognition of its sustainable and socially efficient business solution. The 10 winning teams will participate in a series of local and international events to develop their businesses by building connections, exploring markets, seeking partners and enhancing brand awareness.The Start-up Express Pitching Final winners pictured together with the judging panel and special guests. Ben Cheng, Managing Partner, C Ventures; Jason Chiu, Chairman, Hong Kong Start-up Council; Stephen Liang, Assistant Executive Director, HKTDC; Raymond Yung, Vice Chairman, AMTD Group; and Arshad Chowdhury, Managing Partner, Betatron Venture Group [back row, L-R]The distinguished judging panel witnessed the rise of the latest cohort of Start-up Express winnersRenowned stand-up comedian Vivek Mahbubani was the event's host, taking the opportunity to chat with entrepreneurs from some of the participating start-upsStephen Liang, HKTDC Assistant Executive Director, said: "As the pandemic situation gradually begins to ease, innovative business models and ideas will become a new stimulus for the economy in post-pandemic times. The enrolment for Start-up Express 2022 reflected the great enthusiasm of Hong Kong's entrepreneurs, with 20 shortlisted start-ups coming from a broader spectrum of fields than ever before, including arts tech, green tech, health tech, prop tech, fintech, smart city tech, edtech, food tech and others. Over the past four years, the programme has nurtured 40 start-ups and the HKTDC continues to pass on the spirit of entrepreneurship in Hong Kong, assisting local start-ups in growing their businesses to the next level. At the same time, we strive to create a sustainable and international entrepreneurial ecosystem."Diverse opportunities offered to winning start-upsPitching Final contestants presented their innovative business ideas and responded to questions raised by a distinguished panel of judges as well as the online audience. This year's judging panel comprised Raymond Yung, Vice Chairman, AMTD Group; Jason Chiu, Chairman, Hong Kong Start-up Council; Andrew Young, Associate Director (Innovation), Sino Group; Ben Cheng, Managing Partner, C Ventures; and Arshad Chowdhury, Managing Partner, Betatron Venture Group. The 10 winning start-ups are: Allklear Health, Beth Bioinformatics, Calioo Technologies, Custonomy Company, EggLogics, Flow, Good Food Technologies, i2Cool, MixCare Health and PONS.ai (click here https://tinyurl.com/2p8kvfxs to download the list of winners and their company profiles). The HKTDC will arrange a series of exposure opportunities through which the winning teams can interact with buyers and investors.Outstanding presentations at Pitching FinalAMTD Group was the exclusive Strategic Partner of Start-up Express for the fourth consecutive year. Calvin Choi, Chairman and Chief Executive Officer of AMTD Group and Founder of AMTD IDEA, shared his thoughts on the contest, saying that all the contestants presented extraordinary business ideas. "This is the fourth year that AMTD has supported HKTDC's Start-up Express as an exclusive Strategic Partner. The wide range of start-ups participating in this year's Pitching Final continue to innovate and develop in a more diverse and contemporary way. In particular, we saw more start-ups coming from art tech, food tech and other emerging areas this year, which shows that local start-ups are market-sensitive, quick to respond to the direction and dynamics of emerging industries, as well as reactive to rising trends and fads of the times," Mr Choi said.Noting that local businesses across different sectors had been affected by the pandemic, he added: "It is encouraging to see Hong Kong start-ups remaining active despite the difficulties and on the lookout for opportunities under the new normal. Government policies and the social environment have been very supportive of start-ups, too. I am confident that if local start-ups can continue their efforts, stay flexible and be determined to find unique opportunities in the new normal, they can definitely stand out from their competitors in an ever-changing business environment and find a sustainable way forward."The "SpiderNet Start-up Award", established to recognise the top performer selected by AMTD in the Pitching Final, was awarded to EggLogics. The award aims to provide the winner with an exclusive opportunity to access the resources and network of the AMTD SpiderNet ecosystem. The winner will benefit greatly in terms of its future business development and at the same time create synergies with other entrepreneurs within the ecosystem.Jason Chiu, Chairman of the Hong Kong Start-up Council and a member of this year's judging panel, said: "It is my pleasure to be on the judging panel again this year. There is tremendous competition in this year's contest. All the start-up teams used their innovative mindsets to deliver exceptional pitches and shone through, highlighting the fact that local tech talents are extremely capable. I am confident that Start-up Express will serve as a springboard for the winning teams to access more opportunities. They can leverage this platform to expand their business network, explore markets in Mainland China especially the Greater Bay Area and overseas, and take their business to the next level."Start-up Express boosts brand awareness and network expansionStart-up Express provides start-ups with the chance to promote their business ideas and enhance their brand awareness while connecting with investors and industry leaders, as well as acquiring business know-how from industry experts. Calvin Cheng, founder and CEO of Wizpresso which was a winner in the 2021 Start-up Express, said: "With the assistance provided by the HKTDC, we gained a lot of exposure that helped greatly with our brand promotion. We also had the chance to participate in international trade fairs to connect with potential clients. These are the kind of valuable opportunities open to Start-up Express winners."Logistics platform Zeek, another winning team at last year's Pitching Final, has successfully established a presence in Vietnam, Thailand, Singapore, Malaysia and other markets. KK Chiu, CEO of Zeek, said the company was able to grow its business connections by meeting with different businesses under the coordination of the HKTDC. Through HKTDC-organised local and overseas events, it also gained the opportunity to promote its brand to other local and international businesses.Start-up Express International Edition launches in DecemberThe HKTDC has always given its full support to Hong Kong's entrepreneurial ecosystem, helping to maintain the city's status as a competitive business centre and hub for innovation. In celebration of the fifth anniversary of Start-up Express, the first International Edition of the contest will be held this December as part of HKTDC Entrepreneur Day. Winning teams from Hong Kong will compete with outstanding start-ups from Mainland China, USA, the UK, Germany, Israel, Japan, Korea, Singapore and other countries and regions. Winners in the International Edition will be offered comprehensive assistance to enter the Hong Kong market and explore opportunities in the Guangdong-Hong Kong-Macao Greater Bay Area via the Hong Kong platform.Start-up Express website: https://portal.hktdc.com/startupexpress/en/Photo download: https://bit.ly/3HnvEBWAbout HKTDC The Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on Twitter @hktdc and LinkedInMedia enquiriesPlease contact HKTDC's Communications & Public Affairs Department:Clayton Lauw, Tel: +852 2584 4472, Email: clayton.y.lauw@hktdc.org Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

中国抗体在美国完成SM17 I期临床试验首例健康受试者给药

15 6 月, 2022

HONG KONG, Jun 15, 2022 - (亚太商讯 via SEAPRWire.com) - 中国抗体制药有限公司（“中国抗体”或“公司”，连同其附属公司，统称“集团”；股份代号：3681.HK），专注研究、开发、制造及商业化免疫性疾病疗法的香港生物制药公司，欣然宣布，其一类新药（First-in-Class）SM17（注射用人源化抗IL-17RB单克隆抗体）在美国完成其I期临床试验之首例健康受试者给药，目前受试者情况正常。SM17是一款全球首创针对IL-17RB靶点的人源化IgG4-κ单克隆抗体。SM17最初由LifeArc（英国领先的医药研究慈善组织）与Andrew McKenzie博士共同开发并委托授权给中国抗体进行后续的临床研究与商业化。Andrew McKenzie博士（英国皇家学会会员）也是我们中国抗体科学顾问委员会成员。SM17结合IL-17RB受体后，可抑制人白细胞介素25（IL-25，一类关键的“警戒素”）导致的Th2细胞相关免疫反应，而IL-25已被证明与气道细胞的病毒感染以及过敏性疾病如哮喘的病理变化有关。患有未受控制的严重哮喘疾病患者，会承受哮喘反复发作及住院的风险；未受控制的严重哮喘疾病也会引起死亡率及患病率的升高、生活质素的下降以及医疗支出的增加等一系列问题。公司相信靶向Th2细胞相关炎性上游细胞因子通路（例如IL-17RB）的疗法，将能够在较前端从相关免疫级联反应控制哮喘等气道炎性相关疾病的发生及进展。公司相信SM17有潜力满足现有哮喘治疗中未满足的医疗需求。FIH的I期临床试验主要是在健康受试者中进行单次递增剂量（SAD）研究和多次递增剂量（MAD）研究，目的在于研究SM17在健康受试者中的安全性、耐受性、药效及相关药物代谢反应。SM17新药研究申请（IND）于2022年3月11日获得美国食品药品监督管理局（FDA）批准。尽管疫情爆发，中国抗体依旧快速在美国启动I期临床试验之首例健康受试者给药计划。此次I期临床试验的启动是中国抗体与LifeArc合作的重要里程碑，也从侧面验证了中国抗体在新药研发方面的的高效执行力。LifeArc首席执行官Melanie Lee提到：“LMB在抗体研发领域已深耕多年，LifeArc与Andrew McKenzie博士共同合作开发了SM17。Andrew McKenzies博士研究开发靶向IL-17RB的临床候选药物，然后利用LifeArc的人源化技术将靶向IL-17RB的抗体候选药物人源化，最终得到我们的人源化抗IL-17RB单抗。之后，LifeArc授权中国抗体进一步进行SM17的临床研究与后续商业化开发。我们很高兴SM17已经在美国启动I期临床试验，并完成首例健康受试者给药，希望SM17的顺利开发能够为现有疗法无法改善病情的严重不受控制的疾病患者带来福音。”中国抗体主席、执行董事兼首席执行官梁瑞安博士表示：“SM17已在I期临床试验中顺利完成首例健康受试者给药，SM17 I期临床试验的顺利启动是整个管线研究开发过程的一个重要里程碑。继旗舰产品SM03临床III期病人入组完成，预计2023年申请新药上市，核心产品SN1011适应症范围不断扩大，不同适应症的新药研究申请不断获得监管机构获批并计划在今年开展多项适应症的II期临床试验后，我们的SM17又顺利的进入I期临床，并完成首例健康受试者给药。公司产品管线的不断丰富进一步证明公司同时推进多项研发项目的能力。我们对SM17的临床开发以及商业化机会充满信心，我们将继续加快推进项目，坚持独立创新的理念，为患者谋求福祉、为股东创造价值。”关于LifeArcLifeArc是一家以自筹资金为主，英国领先的医药研究慈善组织。它通过与学术界、工业界、慈善机构和患者团体等展开合作，发掘早期新药项目，帮助新药的研究以满足广大患者未被满足的医疗需求。它在伦敦设有办事处，在斯蒂夫尼奇和爱丁堡设有科研机构，以及一支在伦敦弗朗西斯·克里克研究所工作的专业科学团队。关于中国抗体制药有限公司中国抗体制药有限公司专注于研究、开发、制造及商业化免疫性疾病疗法。公司注重创新研发，其旗舰产品SM03为全球首项用以治疗类风湿关节炎的潜在抗CD22单抗，已在中国进入类风湿关节炎三期临床试验，并被列为国家十三五重大新药创制专项重大项目。此外还有多个同类靶点首创（First-in-target）及同类首创（First-in-class）在研药物，部分已处于临床阶段，适应症范围覆盖类风湿性关节炎、系统性红斑狼疮、寻常型天疱疮、非霍奇金氏淋巴瘤、哮喘等具有重大未满足临床需求的疾病。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

1 …22 23 24 25